SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
NEW YORK, Jan. 25, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of HeartWare International, Inc. (“HeartWare”) (NASDAQ:HTWR) between June 10, 2014 and January 11, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired HeartWare securities June 10, 2014 and January 11, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/heartware.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/heartware.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
